Jeffrey S Weber

Marked Differences in Human Melanoma Antigen-Specific T Cell Responsiveness after Vaccination Using a Functional Microarray

Mark M Davis, Mark M. Davis, Yoav Soen, 2005, PLoS medicine.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

Yu Shyr, Fei Ye, Donald Lawrence, 2012, The New England journal of medicine.

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2013, The New England journal of medicine.

Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma

Jon Richards, Michael B Atkins, M. Atkins, 2010, Clinical Cancer Research.

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

Mario Roederer, M. Betts, M. Roederer, 2003, Nature Medicine.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Antoni Ribas, Caroline Robert, Anthony M Joshua, 2014, The Lancet.